Royalty Pharma names Greg Raskin SVP, head of academic initiatives
Reuters2026/08/03 12:15- Royalty Pharma named Greg Raskin senior vice president, head of academic initiatives, effective August 2026.
- He will lead outreach with academic and non-profit institutions, overseeing the Royalty Pharma Translational Prize.
- Raskin previously served as senior vice president, technology development at Memorial Sloan Kettering Cancer Center, leading tech transfer and startup formation.
- Earlier roles include vice president at AllianceBernstein’s venture fund, biotech analyst at Baker Brothers Investments, consultant at McKinsey.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen consolidates near August highs vs USD as hawkish BoJ, Fed bets clash
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Crypto prices
More
